SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Directorate Change

5 Mar 2010 07:00

RNS Number : 1295I
Rentokil Initial PLC
05 March 2010
 



5 March 2010

 

 

 

Rentokil Initial to appoint Jeremy Townsend as Chief Financial Officer

 

Rentokil Initial plc (FTSE: RTO) today announces that Jeremy Townsend will be appointed to the Board as a Director and Chief Financial Officer on leaving his current role.

 

Jeremy Townsend, 46, is currently Finance Director at Mitchells & Butlers, a role he has held since February 2008. Jeremy joined Mitchells & Butlers in June 2005 as Deputy Finance Director. He was previously employed by J Sainsbury plc where he held various finance roles including Group Financial Controller, Corporate Finance Director and Strategy Director. Prior to Sainsbury's, he was employed by Ernst & Young, working in audit and corporate finance. Jeremy is a Fellow of the Institute of Chartered Accountants of England and Wales.

 

The date on which he will join the Board will be announced in due course.

 

Rentokil Initial's current CFO, Michael Murray, indicated some time ago that he would be minded to seek a new challenge outside Rentokil Initial if a suitable replacement could be identified. Mr Murray will leave the Board on 31 March 2010.

 

Alan Brown, Chief Executive Officer of Rentokil Initial plc, said: "We are delighted that Jeremy has chosen to join Rentokil Initial. He has highly relevant experience in managing the financial aspects of a business that operates across many sites with many brands. His expertise will be invaluable as we continue to pursue our Operational Excellence agenda.'

 

"On behalf of the Board I would like to wish Michael well for the future and thank him for his contribution during his time with the group."

There is nothing that is required to be disclosed under Listing Rule 9.6.13 in respect of Jeremy Townsend.

Ends

For further information:

Media enquiries:

Malcolm Padley, Corporate Communications Rentokil Initial plc 07788 978199

Kate Holgate, Tom Williams Brunswick Group 020 7404 5959

 

Shareholder/analyst enquiries:

Katharine Rycroft, Investor Relations Rentokil Initial plc 07811 270734

 

About Rentokil Initial

Rentokil Initial is one of the largest business services companies in the world, operating in all the major economies of Europe, North America, Asia Pacific and Africa.

www.rentokil-initial.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUGUPAWUPUGRC
Date   Source Headline
29th Aug 20187:00 amRNSDirector/PDMR Shareholding
20th Aug 201812:44 pmRNSDirector/PDMR Shareholding
1st Aug 20183:12 pmRNSHolding(s) in Company
31st Jul 20187:00 amRNSInterim Results
27th Jul 20185:07 pmRNSHolding(s) in Company
5th Jul 20184:52 pmRNSHolding(s) in Company
5th Jul 201811:36 amRNSDirector Declaration
28th Jun 20184:10 pmRNSHolding(s) in Company
7th Jun 20185:16 pmRNSDirector Declaration
17th May 20184:12 pmRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSNotice of Capital Markets Days
9th May 20185:40 pmRNSResult of AGM
4th May 20184:27 pmRNSDirector/PDMR Shareholding
2nd May 201810:52 amRNSDirector/PDMR Shareholding
1st May 20186:00 pmRNSDirector/PDMR Shareholding
30th Apr 20185:48 pmRNSDirector/PDMR Shareholding
26th Apr 20183:24 pmRNSHolding(s) in Company
25th Apr 20184:50 pmRNSHolding(s) in Company
24th Apr 20183:55 pmRNSHolding(s) in Company
24th Apr 201810:53 amRNSHolding(s) in Company
20th Apr 20184:09 pmRNSDirector/PDMR Shareholding
19th Apr 20184:32 pmRNSHolding(s) in Company
19th Apr 20187:00 amRNSQ1 Trading Update
5th Apr 201812:57 pmRNSHolding(s) in Company
5th Apr 201811:06 amRNSAnnual Financial Report
4th Apr 20186:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20184:12 pmRNSBlock listing Interim Review
29th Mar 201811:55 amRNSTotal Voting Rights
27th Mar 20184:01 pmRNSHolding(s) in Company
27th Mar 201812:58 pmRNSAdditional Listing
8th Mar 20185:50 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSFinal Results
27th Dec 20177:00 amRNSDirector/PDMR Shareholding
20th Dec 20173:40 pmRNSDirector/PDMR Shareholding
22nd Nov 20174:30 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSIssue of new EUR400m bond
13th Nov 20174:35 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSPurchase of Vector Disease Acquisition LLC
7th Nov 20174:14 pmRNSHolding(s) in Company
6th Nov 20177:00 amRNSDirectorate Change
2nd Nov 20176:07 pmRNSHolding(s) in Company
1st Nov 20177:00 amRNSDirectorate Change
19th Oct 20177:00 amRNSQ3 Trading Update
2nd Oct 20173:26 pmRNSBlock listing Interim Review
21st Sep 20177:00 amRNSDirectorate Change
18th Sep 20177:00 amRNSDirectorate Change
22nd Aug 20173:34 pmRNSChange to Director's details
4th Aug 201711:57 amRNSDirector/PDMR Shareholding
31st Jul 20172:16 pmRNSDirector Declaration
27th Jul 20177:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.